RNS Number : 6392U
  Dermasalve Sciences PLC
  16 May 2008
   


    DermaSalve Sciences plc

    ("DermaSalve" or the "Company")

    Statement re Share Price Movement   


    The Directors of DermaSalve note the recent rise in the Company's share price and comments in the press today.

    Pursuant to the convertible loan agreement with Trafalgar Capital Specialised Investment Fund ("Trafalgar") announced on 5 October 2007,
a total of 3,263,851 ordinary shares have been issued by the Company to Trafalgar in six separate tranches from 5 October 2007 to 12 March
2008.  The Directors understand that Trafalgar has subsequently sold these shares providing a regular supply of new shares into the market.
Trafalgar elected not to convert any portion of the convertible loan in April and the Company made a cash repayment of £23,892.  On 15 May
2008 the Company agreed an alternative cash payment plan with Trafalgar which will result in no further shares being issued to Trafalgar for
the foreseeable future.    

    The Directors are not aware of any other specific reason for the increase in the Company's share price.


    Enquiries:


 DermaSalve Sciences plc             +44 (0)191 260 5070
 Dr. Mark Randle, CEO
 Phil Pattison, Finance Director
                                     www.dermasalve.com

 Hanson Westhouse Limited            +44 (0)113 246 2610
 Tim Feather / Matthew Johnson

 Hansard Group                       +44 (0)20 7245 1100
 Adam Reynolds / Brendan Adams

This information is provided by RNS
The company news service from the London Stock Exchange
 
  END 
 
SPMGUUGGAUPRGUQ
Dermasalve Sciences (LSE:DRM)
Gráfica de Acción Histórica
De Oct 2024 a Nov 2024 Haga Click aquí para más Gráficas Dermasalve Sciences.
Dermasalve Sciences (LSE:DRM)
Gráfica de Acción Histórica
De Nov 2023 a Nov 2024 Haga Click aquí para más Gráficas Dermasalve Sciences.